Post-Marketing Surveillance Study of OTEZLA

Amgen

Status: Completed

Conditions: Psoriasis

Study type: Observational

Funder types: Industry

Identifiers

NCT03284879

CC-10004-PSOR-018

Details and patient eligibility

About

To evaluate the safety and efficacy of OTEZLA in actual clinical settings of use in patients with Psoriasis vulgaris that is with an inadequate response to topical therapies and Psoriasis arthropathica

1. Planned registration period 2 years
2. Planned surveillance period for 4 years from 6 months after launch

Enrollment: 1,086 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

- Patients who have received a diagnosis of either of the following diseases and have received OTEZLA for the first time will be included in this survey.

• Psoriasis vulgaris that is with an inadequate response to topical therapies
• Psoriasis arthropathica

Exclusion criteria

• N/A

Trial design

1,086 participants in 1 patient group

Patients with PsV and PsA treated with OTEZLA Tablets

Description:

Patients with psoriasis vulgaris and patients with psoriatic arthritis who are treated with OTEZLA Tablets